Imatinib/nilotinib/various other drugs
- PDF / 141,534 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 44 Downloads / 186 Views
1
XS
Various toxicities: 3 case reports Three patients with concomitant HIV infection and BCRABL-positive chronic myeloid leukaemia (CML) developed various toxicities while receiving imatinib, nilotinib and various other drugs [routes, dosages and outcomes not stated; not all indications and durations of treatment to reactions onset stated]. A 35-year-old man receiving imatinib developed oedema and muscle cramps, requiring dose reduction. A 59-year-old woman developed DRESS syndrome approximately 2 weeks after starting imatinib and 6 weeks after starting allopurinol. Imatinib and allopurinol were discontinued, leading to resolution of her skin rash and liver and kidney involvement. She later developed tuberculosis with hepatotoxicity due to combination therapy with hydroxycarbamide [hydroxyurea], antituberculars and antiretrovirals. She was switched to nilotinib, and rifampicin and efavirenz were added to her regimen. She subsequently developed abnormal plasma concentrations of nilotinib due to the concomitant use of enzyme inducers. The dosage of nilotinib was increased, but she developed neutropenia. A 31-year-old woman developed nausea, vomiting and muscle cramps during treatment with imatinib. Author comment: "The most common side-effect on tyrosine kinase inhibitors was muscle cramps in two of the patients. Other side-effects included oedema and nausea and vomiting." Webb MJ, et al. Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection. International Journal of Hematology 95: 556-563, No. 5, May 2012. Available from: URL: http://dx.doi.org/10.1007/s12185-012-1073-2 - South 803076248 Africa
0114-9954/10/1417-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 1 Sep 2012 No. 1417
Data Loading...
